Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko, L.M., Jakob, C.G., Edalji, R.P., Qiu, W., Montgomery, D., Digiammarino, E.L., Hansen, T.M., Risi, R.M., Frey, R., Manaves, V., Shaw, B., Algire, M., Hessler, P., Lam, L.T., Uziel, T., Faivre, E., Ferguson, D., Buchanan, F.G., Martin, R.L., Torrent, M., Chiang, G.G., Karukurichi, K., Langston, J.W., Weinert, B.T., Choudhary, C., de Vries, P., Van Drie, J.H., McElligott, D., Kesicki, E., Marmorstein, R., Sun, C., Cole, P.A., Rosenberg, S.H., Michaelides, M.R., Lai, A., Bromberg, K.D.(2017) Nature 550: 128-132
- PubMed: 28953875 
- DOI: 10.1038/nature24028
- Primary Citation of Related Structures:  
5KJ2 - PubMed Abstract: 
The dynamic and reversible acetylation of proteins, catalysed by histone acetyltransferases (HATs) and histone deacetylases (HDACs), is a major epigenetic regulatory mechanism of gene transcription and is associated with multiple diseases. Histone deacetylase inhibitors are currently approved to treat certain cancers, but progress on the development of drug-like histone actyltransferase inhibitors has lagged behind ...